Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Adma Biologics (ADMA) Long-Term Debt Issuances (2017 - 2025)

Adma Biologics (ADMA) has disclosed Long-Term Debt Issuances for 8 consecutive years, with -$75.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$75.0 million, compared with a TTM value of $60.0 million through Dec 2025, down 55.56%, and an annual FY2023 reading of $135.0 million, down 11.04% over the prior year.
  • Long-Term Debt Issuances was -$75.0 million for Q4 2025 at Adma Biologics, down from $135.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $151.8 million in Q1 2022 and bottomed at -$75.0 million in Q4 2025.
  • Average Long-Term Debt Issuances over 3 years is $70.6 million, with a median of $135.0 million recorded in 2023.